- Home
- INKT vs ZTEK Comparison
INKT vs ZTEK Comparison
Compare INKT & ZTEK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INKT | ZTEK |
|---|---|---|
| Founded | 2017 | 2008 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.6M | 68.8M |
| IPO Year | 2021 | 2022 |
Fundamental Metrics
Financial Performance| Metric | INKT | ZTEK |
|---|---|---|
| Price | $9.46 | $0.55 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $35.00 | N/A |
| AVG Volume (30 Days) | ★ 155.7K | 122.2K |
| Earning Date | 05-14-2026 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.66 | $0.54 |
| 52 Week High | $76.00 | $1.84 |
Technical Indicators
Market Signals| Indicator | INKT | ZTEK |
|---|---|---|
| Relative Strength Index (RSI) | 46.51 | 34.43 |
| Support Level | $6.80 | $0.55 |
| Resistance Level | $12.64 | $0.75 |
| Average True Range (ATR) | 0.86 | 0.04 |
| MACD | -0.06 | -0.00 |
| Stochastic Oscillator | 18.70 | 15.38 |
Price Performance
Historical ComparisonAbout INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
About ZTEK Zentek Ltd.
Zentek Ltd is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection, and treatment. It is focused on commercializing ZENGuard, a patent-pending coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as pharmaceutical products against infectious diseases.